Yuanling F. Yu

Changping, 102206, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1.

Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1.

Journal: The Lancet. Infectious diseases
Published: July 22, 2026

Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groups.

Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groups.

Journal: Cell reports
Published: December 05, 2025

A Pseudovirus-Based Method for the Simultaneous Quantitation of Neutralization Antibodies Against All Three Poliovirus Serotypes.

A Pseudovirus-Based Method for the Simultaneous Quantitation of Neutralization Antibodies Against All Three Poliovirus Serotypes.

Journal: MedComm
Published: July 03, 2025

Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1.

Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1.

Journal: The Lancet. Infectious diseases
Published: April 30, 2025

High-throughput pseudovirus neutralisation maps the antigenic landscape of influenza A/H1N1 viruses.

High-throughput pseudovirus neutralisation maps the antigenic landscape of influenza A/H1N1 viruses.

Journal: EBioMedicine
Published: January 17, 2025

Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.

Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.

Journal: The Lancet. Infectious diseases
Published: December 30, 2024

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.

Journal: The Lancet. Infectious diseases
Published: October 22, 2024

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.

Journal: Emerging microbes & infections
Published: October 03, 2024

Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine.

Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine.

Journal: Emerging microbes & infections
Published: October 03, 2024

Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.

Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.

Journal: Nature microbiology
Published: September 29, 2024

The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.

The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.

Journal: Journal of medical virology
Published: September 11, 2024

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.

Journal: Nature
Published: June 18, 2024
Showing 1-12 of 45

Last Updated: 09/26/2026